| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6352998 | BAUSCH | Pharmaceutical compositions |
Oct, 2015
(8 years ago) | |
|
US6352998 (Pediatric) | BAUSCH | Pharmaceutical compositions |
Apr, 2016
(8 years ago) | |
| US5912238 | BAUSCH | Heteroatoms-containing tricyclic compounds |
Jun, 2016
(7 years ago) | |
|
US5912238 (Pediatric) | BAUSCH | Heteroatoms-containing tricyclic compounds |
Dec, 2016
(7 years ago) | |
| US6423722 | BAUSCH | Crystalline macrolides and process for their preparation |
Jun, 2018
(5 years ago) | |
|
US6423722 (Pediatric) | BAUSCH | Crystalline macrolides and process for their preparation |
Dec, 2018
(5 years ago) | |
Elidel is owned by Bausch.
Elidel contains Pimecrolimus.
Elidel has a total of 6 drug patents out of which 6 drug patents have expired.
Expired drug patents of Elidel are:
- US6352998
- US6352998*PED
- US5912238
- US5912238*PED
- US6423722
- US6423722*PED
Elidel was authorised for market use on 13 December, 2001.
Elidel is available in cream;topical dosage forms.
The generics of Elidel are possible to be released after 26 December, 2018.
Drugs and Companies using PIMECROLIMUS ingredient
Market Authorisation Date: 13 December, 2001
Treatment: NA
Dosage: CREAM;TOPICAL
More Information on Dosage
ELIDEL family patents
